Table 4

 Efficacy data at last visit for patients with RA in the ARMADA trial/open label extension who were eligible for corticosteroid and/or MTX dosage adjustments*

Drug changeMean duration of RA at baseline (years)ACR20 (%)ACR50 (%)ACR70 (%)DAS28 (mean change from baseline)DAS28 <2.6 (%)HAQ (mean change from baseline)
*Patients were eligible for corticosteroid and/or MTX dosage reductions after receiving adalimumab treatment for at least 6 months. Last visits were at 8–59 months from the start of adalimumab treatment.
Steroid decrease (n = 51)10.8785528–2.922–0.67
Steroid no change (n = 29)11.6765224–2.518–0.58
MTX decrease (n = 92)11.1755534–2.727–0.73
MTX no change (n = 110)12.3674424–2.516–0.65
MTX increase (n = 15)14.5533320–1.77–0.55
MTX and steroid decrease (n = 25)10.1764820–3.024–0.65